Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01400971 · ClinicalTrials.gov registry record
An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes
A clinical trial, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- 4,299
- Enrollment target
NCT01400971: Completed study, sponsored by Eli Lilly and Company.
NCT01400971 is a clinical trial that has completed, run by Eli Lilly and Company. The registered enrollment target is 4,299 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01400971 has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- 4,299 participants
- Enrollment target
Study Summary
The purpose of this study is to identify specific patient, physician, and health system related factors associated with the progression to a more intensive regimen from initial insulin therapy for patients with type 2 diabetes.
Primary Outcome
Multivariable logistic regression model examined baseline participant-, physician-, and healthcare system-related factors associated with the occurrence of any change in insulin therapy. Discrimination domain of the Interpersonal Processes of Care Survey \[IPC\] ranges from 1-5 with higher scores indicating more discrimination and Diabetes Distress Scale ranges from 1-6 with higher scores indicating more distress.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,299 participants |
| Start Date | 2011-07 |
| Est. Completion | 2015-09 |
What the finished NCT01400971 record still lists
NCT01400971 is an observational study that tracks outcomes without assigning an intervention. Its 4,299 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT01400971 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01400971 about?
NCT01400971 is a clinical study titled "An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes". The purpose of this study is to identify specific patient, physician, and health system related factors associated with the progression to a more intensive regimen from initial insulin therapy for patients with type 2 diabetes.
What is the current status of trial NCT01400971?
This trial is currently completed. The enrollment target is 4,299 participants. The study started on 2011-07. Estimated completion is 2015-09.
Who is sponsoring clinical trial NCT01400971?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05774951 · 4,300 participants · Phase 3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
- NCT05543616 · 4,292 participants · Phase 2
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
- NCT05910567 · 4,346 participants · NA
A Research Study of Abdominal Ultrasound (FAST) in Children With Blunt Torso Trauma
- NCT06492616 · 4,220 participants · Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia